With its Novel Foods deadline just one week away, UK industry pioneers BRITISH CANNABIS are providing a much-needed lifeline to CBD brands.
In just one week’s time, BRITISH CANNABIS will submit multiple Novel Food dossiers to the Food Standards Agency (FSA) to cover both its branded portfolio and its white label client’s CBD food products.
The company is part of both the Association for The Cannabinoid Industry’s (ACI) Safety Consortium study and a newly-announced Primary Authority Partnership with Trading Standards. Both of which should be confidence boosters for consumers and resellers.
CBD businesses in the UK are now being offered a last-minute opportunity to name their products within the BRITISH CANNABIS dossier submission with no upfront costs or commitments.
Several of the CBD industry’s most successful and fastest-growing CBD brands have already switched their manufacturer to being powered by BRITISH CANNABIS™ in the wake of Novel Foods and post-Brexit supply chain issues.
With its Novel Foods deadline just seven days away, the industry-original and early pioneer, is providing a much-needed lifeline to CBD brands to piggyback a products’ name onto its applications.
While no company’s applications have been validated yet by the FSA, the target date to allow the recommended six weeks needed to gain validation of submitted Novel Food dossiers prior to 31 March is rapidly approaching.
With many UK brands searching urgently for assistance to secure Novel Food validation, as a market-leading manufacturer and brand-builder, BRITISH CANNABIS is well positioned to assist those brands that are struggling to stay on the market. This could give businesses peace-of-mind by providing another option to ensure their brands remain on the UK market.
From 1 April 2021, the FSA have indicated that various Trading Standards authorities will begin to remove CBD products from sale if a novel food dossier for that product is not received and validated before then.
Ensuring BRITISH CANNABIS™ Passes the Test
The manufacturing and quality control systems throughout the BRITISH CANNABIS supply chain ensure that finished products meet the requirements of the Novel Food regulations, from both a regulatory and commercial perspective.
A 90-day OECD 408 Toxicity Study undertaken by BRITISH CANNABIS, in conjunction with the ACI, on its primary ingredient will assess the effects that different delivery methods (ingestion, absorption, and inhalation) can have on the liver, and if there are any groups (children, adolescents, pregnant women) vulnerable to CBD’s effects.
The company is also undertaking a Cannabinoids Stability Programme on five independently produced batches of primary ingredient, in addition to testing its finished products. This programme is designed primarily to meet the “stability” assessment requirements of regulators.
As the BRITISH CANNABIS family of brands included in its application have been on the market for up to five years and their primary ingredients used in over one million product units, there is substantial usage data and evidence of safety as part of their dossier. This supports the product’s risk assessment and that they pose no risk to public health.
Providing enhanced protection from enforcement via manufacturing facilities based in England, BRITISH CANNABIS is not reliant on European supply for finished products. Upon achieving novel foods application validation, the company will thus see their complete onwards supply chain covered.
At this time, in both Scotland and the European Union, there exists a continued grey area with no set timelines for novel food action. This poses some brands a risk of enforcement for a further period of one or more years for applications to be fully authorised.
For brands made in England however, the starting line for successful brands comes as soon as 1 April 2021.
A Trading Standards partnership, formalised by the Home Office in January 2021, sees BRITISH CANNABIS, the ACI and Buckinghamshire and Surrey Trading Standards working in partnership to embed regulatory compliance into the rapidly developing CBD sector.
Being one of only a handful of UK companies included in the partnership will provide BRITISH CANNABIS and its white label clients further protection across the country.
CEO, Tom Whettem, commented on these developments: “We have considered every safety aspect when painstakingly preparing dossiers for these 200+ products. Our partnership with the ACI has been vital for this and the support we have received as part of our membership has been invaluable for both me and the leadership team in this family-owned business.”
He added: “Our products have now been on the market approaching six years, shipping hundreds of thousands of units and gaining thousands of fans and positive reviews in the process. It is a big motivator to me and my executive team that these customers can continue to have their lives made better by having reliable, effective, legal, cannabis-derived food supplements remain available as part of their diet.”
BRITISH CANNABIS has also seen a significant increase in its market share as the UK halts CBD imports from Europe following the implementation of Brexit; with many brands facing issues with border forces and interruptions to their supply chain.
With reports already that some products are being impounded and destroyed, it is a worrying time for many CBD brands.
Fortunately, this has not affected BRITISH CANNABIS and as a result some of the biggest and most loved brands have switched to this manufacturer in recent weeks.
These clients, new and existing, benefit from the rigorous in-house third-party product and batch testing that BRITISH CANNABIS has carried out for several years.
This ensures its products continue to meet the newly updated Home Office guidance on analytical limits for controlled cannabinoids.
Whettem concluded: “We are open to all suggestions from brand owners who want to see their products’ futures secured. Linking your brand to one of our dossiers does not obligate you to have your brand manufactured by us or to our formulas, but it may be a contingency plan you should think about having up your sleeve as we enter these crucial few weeks.”
BRITISH CANNABIS™ can be reached on +44 (0) 203 965 2420 or via email at firstname.lastname@example.org
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- Cannabis more ‘advantageous’ than conventional sleep aids
- Four20 Medical Cannabis Products Launched in the UK via Rokshaw
- The potential of Medical Cannabis in diabetes management
- Cannabis explained6 months ago
What is HHC? Its effects, safety and legal status in Europe
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy5 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns